Hoyer Bimba F, Manz Rudolf A, Radbruch Andreas, Hiepe Falk
Department of Medicine (Rheumatology and Clinical Immunology), Charité-University Hospital Berlin, Schumannstr. 20/21, D-10117 Berlin, Germany.
Ann N Y Acad Sci. 2005 Jun;1050:124-33. doi: 10.1196/annals.1313.014.
The current view holds that chronic autoimmune diseases are driven by the continuous activation of autoreactive B and T lymphocytes. However, despite the use of potent immunosuppressants, the production of autoantibodies may persist and contribute to the autoimmune pathology. We recently demonstrated in autoimmune mice that both short-lived plasmablasts and long-lived plasma cells are involved in autoantibody production. While anti-proliferative immunosuppressive therapy and monoclonal anti-CD20 antibody deplete short-lived plasmablasts, long-lived plasma cells survive and continue to produce (auto)antibodies. Thus, strategies for targeting long-lived plasma cells may provide potent new treatment modalities.
目前的观点认为，慢性自身免疫性疾病是由自身反应性B淋巴细胞和T淋巴细胞的持续激活所驱动的。然而，尽管使用了强效免疫抑制剂，自身抗体的产生可能仍会持续，并导致自身免疫性病理变化。我们最近在自身免疫性小鼠中证明，短命浆母细胞和长寿浆细胞都参与了自身抗体的产生。虽然抗增殖免疫抑制疗法和单克隆抗CD20抗体可清除短命浆母细胞，但长寿浆细胞存活下来并继续产生（自身）抗体。因此，针对长寿浆细胞的策略可能会提供有效的新治疗方式。
